Development of new thiosemicarbazones with strong ?-glucosidase and antioxidant action
| dc.contributor.author | Kamal, Memona | |
| dc.contributor.author | Sadeghian, Nastaran | |
| dc.contributor.author | Tokali, Feyzi Sinan | |
| dc.contributor.author | Ismail, Mostafa A. | |
| dc.contributor.author | Taslimi, Parham | |
| dc.contributor.author | Alharthy, Rima D. | |
| dc.contributor.author | Shafiq, Zahid | |
| dc.date.accessioned | 2026-06-21T16:21:53Z | |
| dc.date.created | 2026 | |
| dc.date.issued | 2026 | |
| dc.department | Bartın Üniversitesi | |
| dc.description.abstract | Aim: This study aimed to synthesize a new series of thiosemicarbazone derivatives (4a-r) as multifunctional antidiabetic candidates with dual alpha-glucosidase (alpha-Glu) inhibitory and antioxidant activities to address both hyperglycemia and oxidative stress in diabetes management. Materials and methods: Compounds were synthesized and characterized spectroscopically. The in vitro studies were done on compounds for alpha-Glu inhibitory and metal-chelating properties. The docking studies and MM-GBSA experimental analyses were implemented for the evaluation of binding strength, coupled with 500 ns molecular dynamics in order to validate the stability of the enzyme-ligand complex. ADME prediction tools were employed to evaluate pharmacokinetic suitability. Results: Compound 4d (p-methylbenzyl) showing the strongest alpha-Glu inhibition (IC50 = 206.91 nM, K-i = 235.86 nM), significantly surpassing acarbose. Additionally, 4d demonstrated the most effective antioxidant activity (IC50 = 26.85 & micro;g/mL). Computational findings confirmed its favorable binding free energy (-82.36 kcal/mol) and stable interactions with catalytic residues throughout the MD simulations. ADME predictions indicated good intestinal permeability and 89% oral absorption, suggesting improved pharmacokinetic behavior. Conclusion: Compound 4d emerges as a highly promising dual-function antidiabetic candidate with strong enzymatic inhibition, effective antioxidant action, and desirable drug-like features, making it a valuable lead for future optimization and further biological evaluation. [GRAPHICS] . | |
| dc.description.sponsorship | Deanship of Research and Graduate Studies at King Khalid University, Saudi Arabi [RGP-2/381/47] | |
| dc.description.sponsorship | The authors extend their appreciation to the Deanship of Research and Graduate Studies at King Khalid University, Saudi Arabia, through the large research group program under grant number RGP-2/381/47. | |
| dc.identifier.doi | 10.1080/17568919.2026.2675874 | |
| dc.identifier.endpage | 1494 | |
| dc.identifier.issn | 1756-8919 | |
| dc.identifier.issn | 1756-8927 | |
| dc.identifier.issue | 12 | |
| dc.identifier.orcid | 0000-0002-0820-5372 | |
| dc.identifier.pmid | 42171001 | |
| dc.identifier.scopus | 2-s2.0-105039748562 | |
| dc.identifier.scopusquality | Q2 | |
| dc.identifier.startpage | 1481 | |
| dc.identifier.uri | http://doi.org/10.1080/17568919.2026.2675874 | |
| dc.identifier.uri | https://hdl.handle.net/11772/27548 | |
| dc.identifier.volume | 18 | |
| dc.identifier.wos | WOS:001773205400001 | |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Taylor & Francis Ltd | |
| dc.relation.ispartof | Future Medicinal Chemistry | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.relation.sdg | Goal-03: Good Health and Well-Being | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WoS_20260621 | |
| dc.subject | Aryl Sulfonate | |
| dc.subject | Thiosemicarbazone | |
| dc.subject | Diabetes Mellitus | |
| dc.subject | Antioxidant | |
| dc.subject | Molecular Dynamics | |
| dc.title | Development of new thiosemicarbazones with strong ?-glucosidase and antioxidant action | |
| dc.type | Article | |
| dspace.entity.type | Publication |










